144 related articles for article (PubMed ID: 11103680)
21. [Interest of CSF beta-amyloid1-42 and t-tau protein level determinations for the diagnosis of Alzheimer's disease].
Smach MA; Charfeddine B; Lammouchi T; Dridi H; Ben Othman L; Bennamou S; Limem K
Ann Biol Clin (Paris); 2008; 66(5):531-5. PubMed ID: 18957342
[TBL] [Abstract][Full Text] [Related]
22. Cerebrospinal fluid levels of amyloid beta-protein in Alzheimer's disease: inverse correlation with severity of dementia and effect of apolipoprotein E genotype.
Nitsch RM; Rebeck GW; Deng M; Richardson UI; Tennis M; Schenk DB; Vigo-Pelfrey C; Lieberburg I; Wurtman RJ; Hyman BT
Ann Neurol; 1995 Apr; 37(4):512-8. PubMed ID: 7717688
[TBL] [Abstract][Full Text] [Related]
23. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.
Kanai M; Matsubara E; Isoe K; Urakami K; Nakashima K; Arai H; Sasaki H; Abe K; Iwatsubo T; Kosaka T; Watanabe M; Tomidokoro Y; Shizuka M; Mizushima K; Nakamura T; Igeta Y; Ikeda Y; Amari M; Kawarabayashi T; Ishiguro K; Harigaya Y; Wakabayashi K; Okamoto K; Hirai S; Shoji M
Ann Neurol; 1998 Jul; 44(1):17-26. PubMed ID: 9667589
[TBL] [Abstract][Full Text] [Related]
24. [CSF levels of total tau protein in patients with mild cognitive impairment and Alzheimer's disease].
Kaiser E; Schönknecht P; Hunt A; Thomann PA; Pantel J; Schröder J
Z Gerontol Geriatr; 2008 Dec; 41(6):497-501. PubMed ID: 18327693
[TBL] [Abstract][Full Text] [Related]
25. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment.
Stefani A; Martorana A; Bernardini S; Panella M; Mercati F; Orlacchio A; Pierantozzi M
J Neurol Sci; 2006 Dec; 251(1-2):124-8. PubMed ID: 17097109
[TBL] [Abstract][Full Text] [Related]
26. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.
Motter R; Vigo-Pelfrey C; Kholodenko D; Barbour R; Johnson-Wood K; Galasko D; Chang L; Miller B; Clark C; Green R
Ann Neurol; 1995 Oct; 38(4):643-8. PubMed ID: 7574461
[TBL] [Abstract][Full Text] [Related]
27. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Clark C; Kerkman D; DeBernardis J; Li J; Lair L; Reisberg B; Tsui W; Rusinek H
J Intern Med; 2004 Sep; 256(3):205-23. PubMed ID: 15324364
[TBL] [Abstract][Full Text] [Related]
28. Cerebrospinal fluid neuron-specific enolase: a further marker of Alzheimer's disease?
Palumbo B; Siepi D; Sabalich I; Tranfaglia C; Parnetti L
Funct Neurol; 2008; 23(2):93-6. PubMed ID: 18671910
[TBL] [Abstract][Full Text] [Related]
29. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies.
Mollenhauer B; Steinacker P; Bahn E; Bibl M; Brechlin P; Schlossmacher MG; Locascio JJ; Wiltfang J; Kretzschmar HA; Poser S; Trenkwalder C; Otto M
Neurodegener Dis; 2007; 4(5):366-75. PubMed ID: 17622779
[TBL] [Abstract][Full Text] [Related]
30. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.
van der Vlies AE; Verwey NA; Bouwman FH; Blankenstein MA; Klein M; Scheltens P; van der Flier WM
Neurology; 2009 Mar; 72(12):1056-61. PubMed ID: 19307538
[TBL] [Abstract][Full Text] [Related]
31. The diagnostic value of tau protein, beta-amyloid (1-42) and their ratio for the discrimination of alcohol-related cognitive disorders from Alzheimer's disease in the early stages.
Kapaki E; Liappas I; Paraskevas GP; Theotoka I; Rabavilas A
Int J Geriatr Psychiatry; 2005 Aug; 20(8):722-9. PubMed ID: 16035118
[TBL] [Abstract][Full Text] [Related]
32. [The measurement of phosphorylated tau in human cerebrospinal fluid as a diagnostic marker for Alzheimer's disease].
Urakami K; Ito N; Arai H; Ishiguro K; Ohno H; Nakashima K
Seishin Shinkeigaku Zasshi; 2003; 105(4):393-7. PubMed ID: 12806900
[TBL] [Abstract][Full Text] [Related]
33. Increased tau protein level in postmortem cerebrospinal fluid.
Morihara T; Kudo T; Ikura Y; Kashiwagi Y; Miyamae Y; Nakamura Y; Tanaka T; Shinozaki K; Nishikawa T; Takeda M
Psychiatry Clin Neurosci; 1998 Feb; 52(1):107-10. PubMed ID: 9682942
[TBL] [Abstract][Full Text] [Related]
34. Antipsychotic medication is associated with selective alterations in ventricular cerebrospinal fluid Aβ 40 and tau in patients with intractable unipolar depression.
Clarke NA; Hartmann T; Jones EL; Ballard CG; Francis PT
Int J Geriatr Psychiatry; 2011 Dec; 26(12):1283-91. PubMed ID: 21308788
[TBL] [Abstract][Full Text] [Related]
35. Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease.
Bjerke M; Zetterberg H; Edman Å; Blennow K; Wallin A; Andreasson U
J Alzheimers Dis; 2011; 27(3):665-76. PubMed ID: 21860087
[TBL] [Abstract][Full Text] [Related]
36. Combined measurement of PEDF, haptoglobin and tau in cerebrospinal fluid improves the diagnostic discrimination between alzheimer's disease and other dementias.
Abraham JD; Calvayrac-Pawlowski S; Cobo S; Salvetat N; Vicat G; Molina L; Touchon J; Michel BF; Molina F; Verdier JM; Fareh J; Mourton-Gilles C
Biomarkers; 2011 Mar; 16(2):161-71. PubMed ID: 21323605
[TBL] [Abstract][Full Text] [Related]
37. No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia.
Arai H; Satoh-Nakagawa T; Higuchi M; Morikawa Y; Miura M; Kawakami H; Seki H; Takase S; Sasaki H
Neurosci Lett; 1998 Nov; 256(3):174-6. PubMed ID: 9855368
[TBL] [Abstract][Full Text] [Related]
38. CSF biomarker profile and diagnostic value in vascular dementia.
Paraskevas GP; Kapaki E; Papageorgiou SG; Kalfakis N; Andreadou E; Zalonis I; Vassilopoulos D
Eur J Neurol; 2009 Feb; 16(2):205-11. PubMed ID: 19146641
[TBL] [Abstract][Full Text] [Related]
39. Apolipoprotein E genotyping and cerebrospinal fluid tau protein: implications for the clinical diagnosis of Alzheimer's disease.
Arai H; Higuchi S; Sasaki H
Gerontology; 1997; 43 Suppl 1():2-10. PubMed ID: 9187933
[TBL] [Abstract][Full Text] [Related]
40. AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis.
Stefani A; Bernardini S; Panella M; Pierantozzi M; Nuccetelli M; Koch G; Urbani A; Giordano A; Martorana A; Orlacchio A; Federici G; Bernardi G
J Neurol Sci; 2005 Oct; 237(1-2):83-8. PubMed ID: 15990115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
